[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593819":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":25,"locations":32,"responsibleParty":86,"collaborators":88,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":10,"studyType":112,"phases":10,"briefSummary":113,"conditions":114,"keywords":119,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Université de Sherbrooke","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients aged 6-18 with suspected asthma, referred by primary care for methacholine BPT",null,"Patients will be recruited from a larger study, Propulsion Santé, which investigates the usefulness of FeNO and BEC in prioritizing patients whith suspected asthma for bronchial provocation testing in primary care. 1,500 participants will be invited to receive spirometry at 3 centers: CHUS, CHUSJ, and Montreal Children's Hospital. If spirometry is non-diagnostic, patients aged 6 to 18 years who are referred for methacholine challenge testing will be offered the opportunity to participate in the DIVE2 study.In addition to a medical assessment and standardized questionnaires (ACQ5, ACT, and EQ-5D), participants will undergo FeNO and BEC measurements, and additional blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, and biobank sample collection). a nasosorption and urine analysis will be performed as part of this protocol.",[13,14],"Diagnostic Test: FeNO","Diagnostic Test: Blood eosinophil count",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DIAGNOSTIC_TEST","FeNO","FeNO will be measured before the bronchial provocation test using a FeNO VIOX device",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"Blood eosinophil count","a blood test will be performed om the day of bronchial provocation test",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Simon Couilard, MD MSc","CONTACT","+1-819-346-1110","15037","s.couillard@usherbrooke.ca",[33,57,69],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"CHU Sainte-Justine","NOT_YET_RECRUITING","Montreal","Quebec","H3T 1C5","Canada","CA",{"type":42,"coordinates":43},"Point",[44,45],-73.58781,45.50884,{"lat":45,"lon":44},[48,52,55],{"name":49,"role":28,"phone":50,"phoneExt":10,"email":51},"Garry Cormier, Inh","+15143454931","garry.cormier.hsj@ssss.gouv.qc.ca",{"name":53,"role":54,"phone":10,"phoneExt":10,"email":10},"Sze Man Tse, MD","PRINCIPAL_INVESTIGATOR",{"name":56,"role":54,"phone":10,"phoneExt":10,"email":10},"Francine Ducharme, MD",{"facility":58,"status":35,"city":36,"state":37,"zip":59,"country":39,"countryCode":40,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"Montreal Children's Hospital","H4A 3H9",{"type":42,"coordinates":61},[44,45],{"lat":45,"lon":44},[64,68],{"name":65,"role":28,"phone":66,"phoneExt":10,"email":67},"Larry Lands, MD","+15144124400","larry.lands@mcgill.ca",{"name":65,"role":54,"phone":10,"phoneExt":10,"email":10},{"facility":70,"status":71,"city":72,"state":37,"zip":73,"country":39,"countryCode":40,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"CIUSSS de l'Estrie - CHUS","RECRUITING","Sherbrooke","J1H 5N4",{"type":42,"coordinates":75},[76,77],-71.89908,45.40008,{"lat":77,"lon":76},[80,84],{"name":81,"role":28,"phone":82,"phoneExt":10,"email":83},"Morgane Gronnier, MD","+18193461110","morgane.gronnier@usherbrooke.ca",{"name":85,"role":54,"phone":10,"phoneExt":10,"email":10},"Simon Couillard, MD",{"type":87,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[89,91,94,97],{"name":90,"class":6},"Association Pulmonaire du Quebec",{"name":92,"class":93},"Fonds de la Recherche en Santé du Québec","OTHER_GOV",{"name":95,"class":96},"Fondation JA DeSève","UNKNOWN",{"name":98,"class":96},"Opération Enfant Soleil","100593819","diagnosing-asthma-with-clinically-accessible-non-invasive-and-efficient-tests-a-child-inclusive-translational-investigation-100593819",false,"NCT07011394","Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation","DIVE 2","Inclusion Criteria:\n\n* Individuals aged 6 to \\\u003C18 years, presenting symptoms suggestive of asthma\n* Patients referred for a methacholine bronchial provocation test by primary care (defined as non-pulmonologist, non-ENT specialist, non-allergist)\n* Spirometry inconclusive\n\nExclusion Criteria:\n\n* Use of an inhaled or systemic corticosteroid in the previous 48 hours;\n* Smoking in the previous 6 hours; history of viral and\u002For bacterial respiratory infection in the past 4 weeks;\n* major cardiopulmonary disease, including: a) chronic obstructive pulmonary disease (COPD), defined by all of the following: i) aged ≥ 40 years , ii) permanent obstruction on spirometry (FEV1\u002FFVC \\\u003C0.7) and iii) a smoking history of \\>10 pack-years or known alpha-1-antitrypsin deficiency, b) lung conditions deemed significant by the investigator, including cystic fibrosis and bronchiectasis, and c) unstable heart disease.","ALL","6 Years","17 Years",{"count":110,"type":111},123,"ESTIMATED","OBSERVATIONAL","Asthma is a common inflammatory respiratory disease affecting 11% of Canadians, but its diagnosis remains challenging, leading to delays in treatment or overtreatment. Spirometry with a reversibility test and bronchial provocation testing (BPT), considered the gold standard, are the reference diagnostic methods. However, access to BPT is limited as it is performed in hospital settings.\n\nType 2 inflammation biomarkers, the fractional exhaled nitric oxide (FeNO) and blood eosinophils (EOS), represent a potential alternative. In addition to their prognostic and theragnostic value, these markers predict a good response to inhaled corticosteroids in individuals aged ≥ 6 years with asthma. However, their use remains restricted to pulmonologists in specialized clinics and is not recommended as a diagnostic tool in Quebec.\n\nDespite studies demonstrating their diagnostic value in specialized settings, these tests remain underexplored in primary care and insufficiently studied in children under 12 years.\n\nThe objective of ou study is to evaluate the relevance and performance of FeNO and blood eosinophils in the diagnosis of asthma in children referred in primary care with non-diagnostic spirometry.",[115,116,117,118],"Diagnosis","Inflammation","Asthma in Children","Asthma",[120,121,122,123],"observationnal study","asthma diagnosis","FeNO and eosinophil blood count","children","2026-04-29",{"date":126,"type":127},"2026-05-06","ACTUAL",{"date":129,"type":127},"2024-04-09",{"date":131,"type":111},"2027-07-01",{"name":5,"class":6},3]